Search research articles
Contact Us
Filters
Showing results (21-30 of 631) with videos related to
Page
of 64
Sort By:
Antiviral Therapy
|
April 25, 2008
Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
Thomas Berg, Giampiero Carosi
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 22, 2021
COVID-19 and the liver - Lessons learned
Toni Herta, Thomas Berg
Journal of Hepatology
|
October 11, 2017
Reply to: "Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?"
Thomas Berg, Jörg Petersen,
Nature Reviews. Neurology
|
February 6, 2013
Peripheral neuropathies: corticosteroids and antivirals in Bell palsy
Thomas Berg, Lars Jonsson
Transplantation
|
November 16, 2005
Prevention of hepatitis B recurrence after liver transplantation
Daniel Seehofer, Thomas Berg
Journal of Hepatology
|
September 20, 2016
Hepatitis C virus - A teacher of clinical research, cell biology and immunology
Xavier Forns, Thomas Berg
Hepatology International
|
September 2, 2022
G-CSF treatment in decompensated liver disease: a double-edged sword?
Cornelius Engelmann, Thomas Berg
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 11, 2018
Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B
Florian van Bömmel, Thomas Berg
The Lancet. Infectious Diseases
|
May 14, 2021
Three are better than one-increasing HBV seroprotection by a tri-antigenic vaccine
Florian van Bömmel, Thomas Berg
Hepatology Communications
|
September 24, 2021
Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B
Florian van Bömmel, Thomas Berg
Page
of 64
Search research articles
Search
Showing results (21-30 of 631) with videos related to
Sort By:
Page
of 64
Antiviral Therapy
|
April 25, 2008
Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
Thomas Berg, Giampiero Carosi
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 22, 2021
COVID-19 and the liver - Lessons learned
Toni Herta, Thomas Berg
Journal of Hepatology
|
October 11, 2017
Reply to: "Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?"
Thomas Berg, Jörg Petersen,
Nature Reviews. Neurology
|
February 6, 2013
Peripheral neuropathies: corticosteroids and antivirals in Bell palsy
Thomas Berg, Lars Jonsson
Transplantation
|
November 16, 2005
Prevention of hepatitis B recurrence after liver transplantation
Daniel Seehofer, Thomas Berg
Journal of Hepatology
|
September 20, 2016
Hepatitis C virus - A teacher of clinical research, cell biology and immunology
Xavier Forns, Thomas Berg
Hepatology International
|
September 2, 2022
G-CSF treatment in decompensated liver disease: a double-edged sword?
Cornelius Engelmann, Thomas Berg
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 11, 2018
Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B
Florian van Bömmel, Thomas Berg
The Lancet. Infectious Diseases
|
May 14, 2021
Three are better than one-increasing HBV seroprotection by a tri-antigenic vaccine
Florian van Bömmel, Thomas Berg
Hepatology Communications
|
September 24, 2021
Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B
Florian van Bömmel, Thomas Berg
Page
of 64